Biotech Startups

IMU Biosciences builds an immune-system analysis platform that measures over 100 million datapoints from a single blood sample across large patient populations, an approach it calls HD Immunology. The company applies this high-resolution immune profiling to uncover immune mechanisms and support precision diagnosis, monitoring, and treatment of disease.

6 investors

Infinitopes develops immunotherapy treatments for cancer, focusing on immune-oncology and antigen discovery solutions aimed at improving patient outcomes and affordability in cancer care.

6 investors

InnaMed makes an at-home blood testing device and accompanying software that let patients run clinical blood tests from home and deliver results into providers' EMR, LIMS, or EDC systems. It serves healthcare providers and researchers with trend analysis and telehealth integration to support prescribing and dosing decisions.

6 investors

InstaDeep is an AI company founded in 2014 that develops machine learning solutions, partnering with organizations like Google DeepMind. The company maintains offices across London, Paris, Berlin, Tunis, Kigali, Cape Town, New York, and San Francisco.

6 investors

Instylla develops resorbable liquid embolic agents for interventional radiology and oncology, including the Embrace Hydrogel Embolic System and the Tembo Embolic System used to embolize hypervascular tumors and occlude peripheral blood vessels. Its products are used by physicians treating hypervascular tumors in the peripheral vasculature.

6 investors

6 investors

Inventia Life Science provides RASTRUM Workflow Paths, tools for generating reproducible 3D cell models for research and drug discovery. The platform offers flexible discovery workflows and predefined validated solutions for teams conducting biological research and assay development.

6 investors

Invivyd is a biopharmaceutical company that develops antibody-based product candidates for the prevention and treatment of serious viral infectious diseases, combining viral surveillance and predictive modeling with antibody engineering. Its pipeline starts with COVID-19 and aims to expand into influenza and other high-need indications.

6 investors

iOnctura is a clinical-stage drug development company developing precision oral small-molecule therapies targeting the tumor-stroma-immune interface, with a pipeline including roginolisib and cambritaxestat in cancers such as uveal melanoma and pancreatic cancer. It serves oncology patients through low-toxicity therapies aimed at extending healthspan.

6 investors

Iridia develops Molecular Avatar Technology that embeds unalterable molecular identities and custom data (text, image, audio, or video) into physical products and materials such as paints, coatings, plastics, and liquids. The technology is aimed at brands seeking product authentication, traceability, and anti-counterfeiting without changing a product's appearance or function.

6 investors

Izote is a fermentation technology company developing an anaerobic process for industrial biomanufacturing. Its system offers predictable performance scaling, extended fermentation runs, and the use of low-cost bioreactors.

6 investors

Jellatech uses cellular agriculture to produce functional, native collagen without animals. The company positions its process as a more sustainable alternative for producing high-quality collagen.

6 investors

Kinaset Therapeutics is a drug developer working on KN-002, a therapeutic candidate for treating severe asthma across patients regardless of the underlying cause of inflammation. The company is advancing toward clinical trials.

6 investors

Kivu Bioscience develops antibody-drug conjugate (ADC) therapeutics in clinical development, advancing a pipeline of cancer treatments through strategic partnerships and collaborations.

6 investors

KSQ Therapeutics develops eTIL therapies—engineered tumor-infiltrating lymphocyte treatments for solid tumors—using its proprietary CRISPRomics platform to identify and target novel therapeutic candidates through genome-wide CRISPR/Cas9 functional genomic screens.

6 investors

Kura Oncology is a company in the oncology/medtech sector that provides grant support for independent medical education programs designed to enhance healthcare professionals' ability to diagnose and treat patients in Kura Oncology's therapeutic areas of interest.

6 investors

LambdaVision develops a protein-based artificial retina designed to restore vision for patients blinded by advanced retinal degenerative diseases such as retinitis pigmentosa and age-related macular degeneration. The implant uses proteins similar to the visual pigment rhodopsin to mimic the light-absorbing function of damaged photoreceptor cells, and its manufacturing leverages space-based production.

6 investors

Lassen Therapeutics is a biotechnology company developing therapeutics targeting IL-11, with a pipeline focused on immune and fibrotic diseases.

6 investors

Latigo Biotherapeutics is a clinical-stage biopharmaceutical company developing non-opioid pain medicines designed to stop pain transmission without addiction risk. The company aims to build a broad pipeline of pain therapeutics by leveraging its team's expertise in pain biology and clinical development.

6 investors

Lembas develops science-backed functional ingredients and supplements for weight management, designed to support fullness and metabolic health. It partners with supplement, food, beverage, and wellness brands to incorporate its clean-label ingredients into bars, shakes, snacks, and boosters.

6 investors

Liberate Medical develops VentFree, a non-invasive respiratory muscle stimulator that uses neuromuscular electrical stimulation to contract abdominal wall muscles in synchrony with exhalation in mechanically ventilated patients. The device is intended to reduce respiratory muscle atrophy and potentially shorten the duration of mechanical ventilation and ICU stays for critical care patients.

6 investors

Life Biosciences is a biopharmaceutical company developing therapies focused on aging and age-related diseases, working across gene therapy and neuroscience programs. It advances drug candidates from discovery through clinical development.

6 investors

Lucent Bio develops sustainable crop nutrition products, including its flagship Soileos micronutrient fertilizer made by upcycling pea, lentil, and oat hulls from food processing. The company serves farmers and food processors in the agri-food sector, with a focus on Canadian agriculture.

6 investors

Lucy develops consumer nicotine products—such as gum—designed as a lower-harm alternative to cigarettes and vapes, aimed at adult smokers looking to switch or reduce dependence. The company frames its work around tobacco harm reduction and aspires to gain FDA approval as a smoking cessation aid.

6 investors